Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

Commitments and Contingencies (Details Textual) - USD ($)					1 Months Ended		3 Months Ended		9 Months Ended
	Jun. 06, 2017	Jan. 09, 2017	Aug. 04, 2016	Feb. 27, 2014	Jul. 24, 2012	Jun. 15, 2012	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Feb. 16, 2016
Commitments and Contingencies (Textual)
License fee payment									$ 7,529
Research recorded fees							$ 4,957,464	$ 5,685,777	13,840,862	$ 13,599,174
Cost of lease agreement	$ 312,660
Accounts payable and accrued expenses							3,450,027		3,450,027		$ 4,194,874
Lease term	7 years 3 months
Lease agreements, Description	The first 4 years, and an annual rate of $341,610 for the remaining period.
Lines of credit									390,874
Deposit							390,825		390,825
Goodwin							200,000		200,000		$ 100,000
Manufacturing Agreement [Member]
Commitments and Contingencies (Textual)
Project estimated cost				$ 6,800,000					1,800,000
Non - refundable institutional fee				$ 600,000
Research and development costs									1,100,000	500,000
CRO Agreement [Member]
Commitments and Contingencies (Textual)
Project estimated cost			$ 4,600,000						700,000	700,000
AbbVie Biotherapeutics Corp [Member]
Commitments and Contingencies (Textual)
Milestones Payments									7,750,000
AbbVie Biotherapeutics Corp [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
License fee payment									3,000,000
Milestones Payments									$ 7,750,000
Description of royalty payment									The Company shall pay to AbbVie Biotherapeutics Corp. on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.
Royalty of net sales percentage									12.00%
First commercial sale period									12 years 6 months
AbbVie Biotherapeutics Corp [Member] \| After first net sales [Member]
Commitments and Contingencies (Textual)
Milestones Payments									$ 1,500,000
AbbVie Biotherapeutics Corp [Member] \| Phase 1 Clinical Trial of a licensed product [Member]
Commitments and Contingencies (Textual)
Milestones Payments					$ 750,000				750,000
Accounts payable and accrued expenses							750,000		750,000
AbbVie Biotherapeutics Corp [Member] \| Phase 2 Clinical Trial of a licensed product [Member]
Commitments and Contingencies (Textual)
Milestones Payments									750,000
Abbott Biotherapeutics Corp [Member] \| After first net sales [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
Net sales in milestones payment									10,000,000
Oak Ridge National Laboratory [Member]
Commitments and Contingencies (Textual)
Research and development costs		$ 700,000							$ 500,000	400,000
Icon Clinical Research [Member]
Commitments and Contingencies (Textual)
Down payment of project estimated cost percentage									12.50%
Down payment for project									$ 1,900,000
Down payment paid in 2007 and 2012									200,000
Total project estimated to cost							$ 2,700,000		2,700,000
Research and development costs									0	500,000
Fred Hutchinson Cancer Research Center [Member] \| License and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Milestones Payments						$ 1,000,000
Description of royalty payment						Royalty payments of 2% of net sales will be due to FHCRC.
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )						$ 200,000
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )						300,000
Research recorded fees									45,000	400,000
Fred Hutchinson Cancer Research Center [Member] \| Maximum [Member] \| License and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration						23,500,000
Fred Hutchinson Cancer Research Center [Member] \| Minimum [Member] \| License and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration						$ 13,200,000
Medpace, Inc. [Member] \| CRO Agreement [Member]
Commitments and Contingencies (Textual)
Total project estimated to cost												$ 7,200,000
Research and development costs									$ 2,700,000	$ 2,600,000